Current Trials

TR-01

Banking of Tissue and Establishing Continuous Cell Lines and Xenografts From Neoplasia

Study Chair: C. Patrick Reynolds, MD PhD
Cancer Center Director
Texas Tech University Health Sciences Center
3601 4th Street, Mailstop 9445
Lubbock, TX 79430-6540
Phone: 806-743-1558
Fax: 806-743-2990
Email: patrick.reynolds@ttuhsc.edu

Trial currently open at: Don and Sybil Harrington Cancer Center, University Medical Center, University of Texas Health Sciences Center San Antonio, TTUHSC (Lubbock, Amarillo and El Paso campuses), Joe Arrington Cancer Center and The University of Texas Southwestern Medical Center

SPOC-2008-01

A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children with Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogeneous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058

Study Chair: Barry Maurer, MD, PhD
Texas Tech University Health Sciences Center SOM Cancer Center
3601 4th Street, STOP 9445
Lubbock, TX 79430-9445
Phone: 806-743-2705
Fax: 806-743-2691
E-mail: barry.maurer@ttuhsc.edu

Trial currently open at: MD Anderson, TTUHSC Lubbock, Oklahoma University Health Sciences Center

SPOC-2010-002

Phase I Trial of Intravenous Fenretinide (4-HPR) plus Intravenous Safingol for Patients with Relapsed Malignancies

Study Chair: David E. Gerber, M.D.
Harold C. Simmons Cancer Center
Division of Hematology/Oncology
5323 Harry Hines Blvd., Mail Code 8852
Dallas, TX 75390-8852
Phone: 214-648-4180
Email: david.gerber@utsouthwestern.edu

Trial currently open at: The University of Texas Southwestern Medical Center, University Medical Center, Joe Arrington Cancer Center.

SPOC-2011-001

Phase I/II Trial of Fenretinide/LXS oral powder (NSC 374551) plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Study Chair: Jayanthi Lea, MD
The University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, TX 75390
Phone: 214-648-2621
Email: jayanthi.lea@utsouthwestern.edu

Trial currently closed to accrual.

SPOC-2012-001

Phase I Dose-Escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Study Co-Chair: Paul Harker-Murray, MD, PhD
Medical College of Wisconsin/Children's Hospital of Wisconsin
8701 Watertown Plank Road
MFRC3018
Milwaukee, WI 53226
Phone: 414-955-4170
Email: pharker@mcw.edu

Study Co-Chair: William Meyer, MD
University of Oklahoma Health Sciences Center
1200 Children's Ave, Suite 14500
Oklahoma City, OK 73104
Phone: 405-271-5311 ext 42545
Email: William-meyer@ouhsc.edu

Trial currently open at: Medical College of Wisconsin/Children's Hospital of Wisconsin, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, University Medical Center and Cincinnati Children's Hospital (pending).

SPOC-2013-001

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients with Recurrent or Resistant Neuroblastoma (IND #: 68,254)

Study Chair: Tanya Watt, MD
Dedman Family Scholar in Clinical Care
Assistant Professor
Pediatric Oncology-Bone Marrow Transplant
Children's Medical Center
University of Texas Southwestern
Dallas, Texas
Phone:214-456-6363 (office)
Email: tanya.watt@UTSouthwestern.edu

Study Vice Chair: Barry J. Maurer, M.D., Ph.D.
Texas Tech University Health Sciences Center
3601 4th St. STOP 9445
Lubbock, TX 79430-9445
Phone: (806) 743-2705
Email: barry.maurer@ttuhsc.edu

Trial currently open at: Cook Children's Hospital, Medical College of Wisconsin/Children's Hospital of Wisconsin, University of Oklahoma Health Sciences Center, The University of Texas Southwestern Medical Center, University of Chicago, and Cincinnati Children's Hospital (pending).

SPOC-2013-001 (Fenretinide + Vincristine for Relapsed Neuroblastoma)

(This video can also be viewed on YouTube.)

SPOC-2014-001

Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder Plus Ketoconazole in Patients with Recurrent or Resistant Neuroblastoma (IND #68,254)

Study Chair: Barry Maurer, MD, PhD
Texas Tech University Health Sciences Center
3601 4th Street, STOP 9445
Lubbock, TX 79430-9445
Phone: 806-743-2705
Email: barry.maurer@ttuhsc.edu

Trial currently open at: Children's Hospital of Philadelphia, Cook Children's Hospital, Medical College of Wisconsin/Children's Hospital of Wisconsin, University of Oklahoma Health Sciences Center, The University of Texas Southwestern Medical Center, Stanford University, Cinncinati Children's Hospital, and University of California, San Francisco.

SPOC-2015-01

Phase 1 trial of dose escalated BGB324 in combination with docetaxel for previously treated advanced non-small cell lung cancer (NSCLC)

Study Chair: David E. Gerber, M.D.
Harold C. Simmons Cancer Center
Division of Hematology/Oncology
5323 Harry Hines Blvd., Mail Code 8852
Dallas, TX 75390-8852
Phone: 214-648-4180
Email: david.gerber@utsouthwestern.edu

Trial currently open at: The University of Texas Southwestern Medical Center

© South Plains Oncology Consortium (2008-2017)